CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Recruiting now · Phase 1/Phase 2

Conditions studied: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma

In brief

Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).

Key facts

Study ID

NCT02259556

Run by

Chinese PLA General Hospital

People needed

30

Starts

2014-10-01

Expected to finish

2029-10-01

Last updated by the study team

2016-01-28

Who can join

Age: 16 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or refractory to 2 multidrug regimens and/or anti-CD30 antibody treatment.
• Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients who are unable to receive or complete standard chemotherapy.
• Karnofsky or Lansky score greater than 60%.
• Expected survival>12 weeks.
• Creatinine<2.5mg/dl.
• ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 fold normal.
• Bilirubin<2.5mg/dl.
• Pulse oximetry of >90% on room air.
• Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.
• Available autologous T cells with 10% or more expression of CD30 CAR determined by flow-cytometry.
• Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.

You may not qualify if…

• Active infection such as hepatitis B or C.
• Receive anti-CD30 antibody-based therapy within recent 6 weeks.
• Current use of systemic corticosteroids.
• Pregnant or lactating.
• Confirmed tumor in pulmonary and archenteric tissues.

Where it is running

• Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.